Therefore, the newly discovered potent inhibitory action of NPs/NPR1-axis on IL-1β secretion in DCs suggest that the targeting of NPs/NPR1 axis could be a promising therapeutic approach for controlling excessive inflammation in autoimmune diseases and chronic inflammatory conditions. Here, IL1B is linked to autoimmune disease.